Lactobacillus delbrueckii subsp. lactis CIDCA is a new potential probiotic strain whose molecular basis attributed to the host’s benefit has been reported. This study investigated the safety aspects of Lactobacillus delbrueckii subsp. lactis CIDCA 133 based on whole-genome sequence and phenotypic analysis to avoid future questions about the harmful effects of this strain consumption. Genomic analysis showed that L. delbrueckii subsp. lactis CIDCA 133 harbors virulence, harmful metabolites, and antimicrobial resistance-associated genes. However, none of these genetic elements is flanked or located within prophage regions and plasmid sequence. At a phenotypic level, it was observed L. delbrueckii subsp. lactis CIDCA 133 antimicrobial resistance to aminoglycosides streptomycin and gentamicin antibiotics, but no hemolytic and mucin degradation activity was exhibited by strain. Furthermore, no adverse effects were observed regarding mice clinical and histopathological analysis after the strain consumption (5 × 10⁷ CFU/mL). Overall, these findings reveal the safety of Lactobacillus delbrueckii subsp. lactis CIDCA 133 for consumption and future probiotic applications.

德氏乳杆菌亚种。lactis CIDCA 是一种新的潜在益生菌菌株，其分子基础归因于宿主的益处已被报道。本研究调查了德氏乳杆菌亚种的安全性。lactis CIDCA 133 基于全基因组序列和表型分析，以避免未来关于这种菌株消耗的有害影响的问题。基因组分析表明，德氏乳杆菌亚种。lactis CIDCA 133 具有毒力、有害代谢物和抗菌素耐药性相关基因。然而，这些遗传元件中没有一个位于或位于前噬菌体区域和质粒序列内。在表型水平上，观察到L. delbrueckii 亚种。lactis CIDCA 133 对氨基糖苷类链霉素和庆大霉素抗生素耐药，但菌株未表现出溶血和粘蛋白降解活性。^{此外，菌株消耗（5 × 10 7}  CFU/mL）后的小鼠临床和组织病理学分析未观察到不良反应。总体而言，这些发现揭示了德氏乳杆菌亚种的安全性。lactis CIDCA 133 用于消费和未来益生菌应用。